Stay Informed with the LICUID Consortium!
Bio-Techne announces exclusive development and license agreement with Thermo Fisher Scientific for out ExoTRU® Kidney Transplantation Rejection Assay! View article here: https://www.prnewswire.com/news-releases/bio-techne-announces-exclusive-development-and-license-agreement-with-thermo-fisher-scientific-for-exotru-kidney-transplant-rejection-assay-301485617.html
Our clinical coordinator, Katharine Cashman, was accepted to the University of Massachusetts Chan Medical School. Congratulations, Kate!
Bio-Techne Announces that the new ExoTRU urine test, developed in collaboration with the Azzi laboratory at the Transplantation Research Center to diagnose Kidney Transplant Rejection, will be offered to patients in 2021. https://www.biospace.com/article/releases/bio-techne-announces-exotru-kidney-transplant-rejection-assay-data-publication/
Our work on the development of a novel urinary exosomal RNA test to diagnose human kidney transplant rejection has been covered by over 20 news outlets. https://www.altmetric.com/details/101279694/news
Our work on the HLA-E restricted CD8 regulatory T cells will be presented in a plenary session at the American Transplant Congress 2021.
Our work on engineering regulatory T cells was mentioned in the “What’s Hot What’s New” session at the 2020 American Transplant Congress